Researchers in computational biology and marine science have combined their diverse expertise and found that trace-metal usage by present-day organisms probably derives from major changes in ocean chemistry occurring over geological time scales.
Current climate change impact models that consider only one weather variable, such as increasing temperature, sometimes spawn unsubstantiated doomsday predictions, according to researchers at Purdue and North Carolina universities.
Natural compounds derived from a sea anemone extract and a shrub plant have been found to block the autoimmune disease response in type-1 diabetes and rheumatoid arthritis, according to University of California, Irvine researchers.
Researchers at the UCLA Henry Samueli School of Engineering and Applied Science today announced they have developed a new reverse osmosis (RO) membrane that promises to reduce the cost of seawater desalination and wastewater reclamation.
“Medicine alone is not enough to get you through cancer,” comments Linda Dibblee, breast cancer survivor and winner of the 2006 Lilly Oncology on Canvas International Art Competition and Exhibition. “You have to stay strong and positive through even the darkest times. Having a channel through which you can release your feelings can help you find strength that you never knew you had. For me, painting became my way of expressing all my thoughts, hopes and frustrations, and I truly believe it played a part in helping me beat cancer.”
Significant errors in insulin dose can result when blood glucose meters are miscoded according to new clinical study. When persons with diabetes use miscoded blood glucose meters to determine how much insulin to take, significant errors in insulin dose can result that may potentially lead to short- and long-term health complications, according to findings of a new study presented at the Sixth Annual Diabetes Technology Meeting in Atlanta, Georgia.
ImClone Systems Incorporated (NASDAQ:IMCL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced results from two randomized Phase III trials of ERBITUX(R) (cetuximab) in patients with metastatic colorectal cancer. These are the first large, randomized studies to examine the impact of ERBITUX treatment on overall survival in colon cancer.
Novartis announced today that Prexige? (lumiracoxib), an oral selective COX-2 inhibitor anti-inflammatory drug, has been cleared for approval in the European Union as a new treatment option for patients suffering from osteoarthritis. This is the most common form of arthritis and a leading cause of chronic pain[2].
Novartis announced plans to build an integrated biomedical Research & Development center in Shanghai’s Zhangjiang Hi-Tech Park that will become an integral part of the Group’s global research and development network.
GlaxoSmithKline (NYSE: GSK) and Adolor Corporation (Nasdaq: ADLR) announced that the Food and Drug Administration (FDA) has issued a letter stating that the new drug application (NDA) for Entereg (alvimopan 12mg) for the management of post operative ileus (POI) is approvable. The FDA has requested 12-month safety data, including analysis of serious cardiovascular events, from study 014 (767905/014), an ongoing safety study in opioid-induced bowel dysfunction (OBD). The FDA also requested a risk management plan as part of the submission.